Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case

Journal of the American Academy of Dermatology

Volumn 42, Issue 4, 2000, Pages 628-632

  Tavadia, Sherine M B ^a   Mydlarski, P Regine ^a   Reis, Marciano D ^a   Mittmann, Nicole ^a   Pinkerton, Peter H ^a   Shear, Neil ^a   Sauder, Daniel N ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL FEATURE; COST BENEFIT ANALYSIS; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; PEMPHIGOID; PLASMAPHERESIS; PRIORITY JOURNAL; SCREENING;

EID: 0033941305     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.103980     Document Type: Article

References (20)

1. Pye RJ. Bullous eruptions. In: Champion RH, Burton JL, Ebling FJG, editors. Rook Wilkinson Ebling textbook of dermatology. Oxford: Blackwell Scientific Publications; 1992. p. 1623-74.
2. Korman NJ. Bullous pemphigoid. Arch Dermatol 1998;134: 1137-41.
3. Tan BB, Lear JT, English JSC. Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 1997;136:351-5.
4. Anstey A. Azathioprine in dermatology: a review in light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995;88:155P-60P.
5. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. Dermatol Clin 1998;16:235-51.
6. Snow JL, Gibson L. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995;32:114-6.
7. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing M, Krynetskaia NF, et al. Thiopurines-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant alleles associated with loss of catalytic activity in whites. Am J Hum Genet 1995;58:694-702.
8. Yates CR, Krynetski Y, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
9. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity; relationship to thiopurine methyl transferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
10. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphisms review. J R Soc Med 1992;85:752-6.
11. Kerstans PJSM, Stolk JN, De Abreu RA, Lambooy LHJ, van de Putte LBA, Boerooms AMT. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:142-5.
12. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997;40:1896-8.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
14. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8.
15. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53: 1051-6.
16. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
17. Jones CD, Smart C, Titus A, Blyden G, Dorvil M, Nwadike N. Thiopurine methyltransferase activity in a sample population of black subjects in Florida. Clin Pharmacol Ther 1993;53:348-53.
18. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
19. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine in dermatologic patients. Arch Dermatol 1995;131:193-7.
20. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenotate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999;40:265-8.